Xenon Pharmaceuticals (NASDAQ: XENE) reported Q1 EPS of ($0.35), $0.06 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $8.8 million versus the consensus estimate of $8.7 million.

For earnings history and earnings-related data on Xenon Pharmaceuticals (XENE) click here.